What was admedus' reduction rate for phase 1? Oh, it was on uninfected patients!
Can you name the differences in the T cell-directed immunotherapies between competitors?
Vaxxas secures funding interest to see if professor Fraser utilizes nanopatch, page-59
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.03 |
Change
-0.470(4.09%) |
Mkt cap ! $233.8M | |||
| Open | High | Low | Value | Volume |
| $11.50 | $11.50 | $10.91 | $89.65K | 8.108K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 525 | $11.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.12 | 369 | 2 |
View Market Depth
| Last trade - 14.09pm 17/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |